[The management of systemic lupus erythematosus with biological therapies]. / Traitement du lupus érythémateux dissémine par les médicaments biologiques.
Rev Med Suisse
; 9(395): 1507-11, 2013 Aug 28.
Article
en Fr
| MEDLINE
| ID: mdl-24024419
ABSTRACT
The efficacy and safety of targeted biological therapies have been analyzed in patients suffering from systemic lupus erythematosus. In renal lupus, infliximab has shown prolonged improvement of the renal function after the induction period (small open studies), whereas abatacept had no significant efficacy (randomised controlled study). In renal and non renal lupus, rituximab did not confirm its efficacy in two randomised controlled studies. In non renal lupus, epratuzumab has shown efficacy in a phase IIb. Belimumab at the high posology of 10 mg/kg has also shown significant efficacy in two large randomised controlled studies.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Lupus Eritematoso Sistémico
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
Fr
Revista:
Rev Med Suisse
Asunto de la revista:
MEDICINA
Año:
2013
Tipo del documento:
Article
País de afiliación:
Bélgica